KLK3 and pachyonychia congenita: The EPI test is included in the 2019 PC Early Detection National Comprehensive Cancer Network guidelines and uses an algorithm independent of clinical features to provide a risk score that discriminates benign/low-grade PC (Grade Group, GG1, ≤15.6) from HGPC (GG2+, >15.6) for men aged ≥50 who are in the PSA “gray zone” (2–10 ng/mL) [9, 10].